Pharm'Up 
Sun Pharmaceutical Industries Limited has launched LEQSELVI™ (deuruxolitinib tablets 8 mg) in the United States for adults with severe alopecia areata, following a patent agreement with Incyte Corporation. The deal, settled in the U.S. District Court for the District of New Jersey, provides Sun Pharma a limited, non-exclusive license to Incyte’s U.S. patents for non-oncology, non-hematology uses, including alopecia areata. The litigation was dismissed with agreed financial terms, including an upfront payment and future royalties.
LEQSELVI is now available across the U.S., offering a once-daily oral treatment for the autoimmune condition causing significant hair loss. “This launch brings a vital new option for patients and providers,” said Richard Ascroft, CEO of Sun Pharma North America, highlighting its role in addressing unmet dermatology needs.
Clinical trials showed one-third of patients regaining nearly all hair by Week 24, with 3% achieving 80% scalp coverage within 8 weeks. Arash Mostaghimi, MD, from Brigham and Women’s Hospital, praised the drug’s consistent efficacy and rapid results, marking it as a key advancement for alopecia areata care.
About the Author
